Greg Kunst, chief executive officer, Aurion Biotech, discussed the potential of cell therapy in treating people with corneal endothelial disease around the world.
Greg Kunst
Advertisement
Chief executive officer, Aurion Biotech
Articles by Greg Kunst
Advertisement
